Clinical Trials Logo

Filter by:
NCT ID: NCT06230224 Recruiting - Clinical trials for B-Cell Non-Hodgkin Lymphoma (B-NHL)

A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma

OLYMPIA-4
Start date: February 15, 2024
Phase: Phase 3
Study type: Interventional

The study is researching an experimental drug called odronextamab, referred to as study drug. The study is focused on patients with previously treated aggressive B-cell non-Hodgkin lymphoma whose cancer has stopped responding to treatment (also known as 'refractory') or has returned (also known as 'relapsed'). The aim of the study is to see how effective the study drug is compared to standard of care (SOC) therapy. The study is looking at several other research questions, including: - What side effects may happen from taking the study drug versus SOC - How much study drug is in your blood at different times - Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects) - Comparing the impact from the study drug versus SOC on your quality-of-life and ability to complete routine daily activities

NCT ID: NCT06229990 Recruiting - Acute Kidney Injury Clinical Trials

Protocol Based-furosemide Stress Test Versus Standard Care to Evaluate Renal Recovery During Continuous Renal Replacement Therapy

PAUSE-CRRT
Start date: January 1, 2024
Phase: Phase 4
Study type: Interventional

Currently, continuous renal replacement therapy (CRRT) is the main modality for renal support in critically ill patients with hemodynamic instability. Most studies have investigated the timing of RRT initiation. However, prolonged CRRT demonstrated the association of many unexpected events, such as catheter-related complications, catheter-related blood stream infection, hypotension, hypothermia, tachycardia, and atrial fibrillation. Up to now, there is a lack of evidence regarding the timing of withholding CRRT. The furosemide stress test (FST) is a tool that is easy to use and has more availability. The investigators aimed to apply FST to evaluate renal recovery compared with standard treatment in critically ill patients undergoing CRRT.

NCT ID: NCT06229951 Not yet recruiting - Clinical trials for Osteo Arthritis Knee

Hydrolyzed Collagen and Undenatured Collagen Type II in OA Knee

Start date: January 20, 2024
Phase: N/A
Study type: Interventional

Randomized controlled trial Targeted patients who come to receive treatment for osteoarthritis that meets the research indications will be assigned to a random group by the box of 4 randomization method, with a sequence that is randomly generated by a computer. The groups are divided into two groups: Group 1: Patients who have taken 480 mg of hydrolyzed collagen and 20 mg of undenatured type II collagen Group 2: Control patients will take placebo Primary outcome : Pain level

NCT ID: NCT06227260 Completed - Clinical trials for Facial Mask From Snake Fruit

Body Massage Oil, Facial Mask, and Ready-to-drink Jelly From Snake Fruit

Start date: March 20, 2023
Phase: Phase 2
Study type: Interventional

This study consisted of three sub-studies including 1) development and evaluation of body massage oil from Snake fruit on skin moisture, elasticity, oiliness, and melanin in healthy participants 2) development and evaluation of facial mask from Snake fruit on skin moisture, elasticity, oiliness, and melanin in healthy participants and 3) development and evaluation of ready-to-drink jelly from Snake fruit on controlling blood glucose and endurance time in healthy participants.

NCT ID: NCT06227104 Recruiting - Clinical trials for Secondary Outcome : 30-day Mortality, Renal Recovery, Length of Hospital Stay

Efficacy of Convection-based HDF Compare With Diffusion-based HD in Sepsis-associated AKI

Start date: June 1, 2023
Phase: N/A
Study type: Interventional

Acute kidney injury (AKI) is a common complication among patient admitted in the hospital worldwide, with estimates of prevalence ranging from less than 1% to 66%.1, 2 In critically ill patients approximately 49% were acute kidney injury network (AKIN) stage 3 which required intensive care unit (ICU) admission, kidney replacement therapy (KRT), and is associated with higher mortality rate.3 Sepsis-associated acute kidney injury (S-AKI) is a frequent complication in critically ill patient and is associated with high morbidity and mortality. S-AKI is defined as AKI in presence of sepsis without other significant contributing factors or simultaneous presence of both Sepsis-3 definition and Kidney Disease Improving Global Outcomes (KDIGO) criteria for AKI. 4, 5 Multicentre studies show that 30-60% of critically ill patient having AKI, and approximately 10-15% require KRT.6 Both Online-hemodiafiltration (OL-HDF) which is convection-based hemodiafiltration and conventional intermittent hemodialysis (IHD) which is diffusion-based hemodialysis are modalities of KRT that can be used to treat AKI in sepsis.7 Conventional intermittent hemodialysis (IHD) involves the removal of waste products and excess fluids from the blood by using a semipermeable membrane that acts as an artificial kidney. However, IHD has limitations in removing certain larger solutes, such as cytokines, which are involved in the inflammatory response associated with sepsis. In contrast, OL-HDF is a more advanced form of hemodialysis (HD) that combines convective clearance with diffusive clearance, resulting in more efficient removal of larger solutes.8 Several studies have suggested that OL-HDF may have advantages over conventional HD in the management of sepsis-associated AKI.9 Some studies found that OL-HDF was associated with improved patient survival and lower incidence of dialysis dependence compared to conventional IHD. Additionally, some studies have suggested that OL-HDF may have anti-inflammatory effects, which could be beneficial in sepsis.9-11 Some observational studies have shown that OL-HDF provide benefit over IHD including, a reduction in the length of ICU stay and a decrease in inflammatory surrogate markers. However, the effect of OL-HDF in improving survival has not yet been established. 1, 7, 9 Some studies have shown that sustained low-efficiency dialysis (SLED) may has advantage in hospital survival in over the continuous veno-venous hemofiltration (CVVH) modality.12 While there are several extracorporeal treatment modalities for AKI in critically ill patients but no randomized study has yet demonstrated a survival benefit over another. A prospective and comparative study between IHD and OL-HDF groups showed no significant difference in mortality between the groups. However, a significant benefit in terms of a reduced length of ICU stays and vasopressor free day was found in the OL-HDF group.13 The past studies show that CRP and IL-6 levels increase in patients treated with IHD and remain stable in patients treated with OL-HDF, with a statistically significant difference. 14 In AKI patient, our aim is to remove small molecules such as uremic toxin or metabolic abnormalities. In chronic kidney disease, the benefit of high flux dialyser or OL-HDF to remove middle to large molecule such as ß2-microglobulin and others chronic inflammation molecules and cytokines through a combination of diffusion-based and convection-based techniques are well-known. These cytokines including C-reactive protein (CRP), interleukin 6 (IL-6), interleukin 10 (IL-10), procalcitonin (PCT), which are commonly elevated in AKI patient, have been shown to be significantly reduced by using hemodiafiltration techniques. 9, 15 However, the benefits of removing middle molecule and inflammatory makers in the acute setting such as AKI in critically ill patient remain controversial.11, 16, 17 Therefore, this study aims to verify the benefit of convection-based treatment in reducing inflammatory molecule such as CRP over diffusion-based treatment in both critically-ill and standard AKI patients. However, it is important to note that OL-HDF requires specialized equipment and may be more complex to administer compared to conventional IHD. Additionally, it is generally more expensive. Therefore, the choice of KRT modality in sepsis-associated AKI should be based on careful consideration of the individual patient's clinical status and available resources.7 It is important to note that every patient's condition is unique and requires individualized treatment, so the specific choice of KRT modality should be made in consultation with a healthcare professional.

NCT ID: NCT06226935 Completed - Clinical trials for Evaluate the Differences in Glaucoma Screening Uptake Among FDRs in Community and Hospital-based

Comparative Analysis of Glaucoma Screening Uptake Among First-Degree Relatives in Community-Based and Hospital-Based Approaches

Start date: January 1, 2022
Phase:
Study type: Observational [Patient Registry]

In conclusion, the study shows that the hospital-based group had a significantly higher screening uptake than the community-based group, reflecting that information from ophthalmologists and registered ophthalmic nurses is more effective and well-received than that from village health volunteers. The study suggests that increasing education and support for village health volunteers could enhance screening uptake. Factors influencing uptake include the age of FDRs, place of residence, education, presenting VA of probands, and treatment of probands. Utilizing this study's findings, spreading knowledge and training health officials at the district and sub-district levels could increase understanding of glaucoma and improve communication with the general public and at-risk groups, potentially increasing the response rate. Additionally, implementing a national free screening glaucoma program for at-risk populations, both in and outside hospitals, and organizing mobile screening units at the district level could be an effective prevention strategy against permanent vision loss from glaucoma.

NCT ID: NCT06226532 Not yet recruiting - Intubation Clinical Trials

Effect of Lidocaine Sprayed for Attenuating Hemodynamic Response During Laryngoscopy and Intubation

Start date: January 2024
Phase: Phase 4
Study type: Interventional

The goal of this clinical trial is to to evaluate the efficacy of lidocaine sprayed at the laryngeal inlet combined with the endotracheal tube cuff compare with intravenous lidocaine on the hemodynamic response to laryngoscopy and intubation in patients undergoing elective neurological procedures during general anesthesia with total intravenous technique. The main question it aims to answer is: - Does topical lidocaine sprayed at the laryngeal inlet combined with the endotracheal tube cuff have more effect on stabilizing hemodynamic responses to laryngoscopy and intubation than intravenous lidocaine, in neurosurgical patients who undergo general anesthesia with total intravenous technique? Participants will be recruited and randomized to receive either lidocaine spray (Group SL) or intravenous lidocaine (group IL) to blunt hemodynamic response to laryngoscopy and intubation.

NCT ID: NCT06226038 Recruiting - Clinical trials for Implant Site Reaction

Effect of Static Magnetic Field on Dental Implant Stability.

Start date: January 1, 2025
Phase: N/A
Study type: Interventional

To evaluate the effect of static magnetic field on dental implant to bone integration.

NCT ID: NCT06223139 Recruiting - COPD Clinical Trials

Association Between Handgrip Strength and Small Airway Disease in Patients With Stable Chronic Obstructive Pulmonary Disease

Start date: January 22, 2024
Phase:
Study type: Observational [Patient Registry]

The goal of this observational study is to investigate the correlation between handgrip strength and small airway disease among patients with chronic obstructive pulmonary disease (COPD). The main question it aims to answer is: • Is handgrip strength correlated with small airway disease in COPD patients? Participants will perform handgrip strength test and impulse oscillometry (IOS).

NCT ID: NCT06221553 Recruiting - Clinical trials for Diffuse Intrinsic Pontine Glioma

Safety and Efficacy of Loco-regional B7H3 IL-7Ra CAR T Cell in DIPG

CMD03DIPG
Start date: March 1, 2024
Phase: Phase 1
Study type: Interventional

A Phase 1 clinical trial to evaluate the safety and early efficacy of CAR T-cell with IL-7Ra signal targeting B7H3 in children with diffuse intrinsic pontine glioma (DIPG) patients after complete standard treatments.